-Largest independent specialty pharmacy in the nation selected as a
participant in the Teva Neuroscience TOP MS research study
-Individuals can enroll by contacting the BioScrip Specialty Pharmacy
Study Coordinator, Kira Botkin at 888-489-7445
BioScrip, Inc. (Nasdaq: BIOS) announced today that Teva Neuroscience
tapped BioScrip Specialty Pharmacy as one of several national research
study participants in one of the most comprehensive MS research studies
announced to date.
TOP MS is a new research study for MS patients. The study will collect
information, through online surveys about the quality of life, symptoms,
relapse, employment, usual level of activity participation and general
health activity from individuals living with MS for a two-year period.
“We are very pleased that BioScrip was selected as a specialty pharmacy
study participant”, said Rick Smith, president and COO of BioScrip Inc.
“Teva recognized our BioscripCare™ MS program’s ability to provide
high-quality, comprehensive and personalized MS care on a national
basis. At BioScrip, we believe that this study will reaffirm our ongoing
commitment to BioscripCare drug therapy adherence programs for patients
and physician support services to improve the quality of life for the MS
patient.”
“Through the TOP MS study, Teva Neuroscience seeks to enhance our
understanding of the issues facing MS patients, further demonstrating
our ongoing commitment to the MS community” said MerriKay Oleen-Burkey,
project leader, TOP MS Study, Teva Neuroscience. “As one of the nation’s
leading specialty pharmacies in MS care, BioScrip’s selection as a
partner in the TOP MS study is a recognition of their comprehensive
approach to MS therapy management."
The research study will recruit approximately 3,000 participants from
several specialty pharmacies nationwide. Individuals should call the
BioScrip Specialty Pharmacy Study Coordinator, Kira Botkin at
888-489-744 or by email at TOPMS@bioscrip.com.
Following your conversation with Ms. Botkin, you will receive an
information packet in the mail which outlines the details of the study.
About BioScrip Inc.
BioScrip, Inc. (www.bioscrip.com)
(Nasdaq: BIOS) is a specialty pharmaceutical healthcare organization
that partners with patients, physicians, healthcare payors and
pharmaceutical manufacturers to provide access to medications and
management solutions to optimize outcomes for chronic and other complex
health care conditions.
Forward Looking Statements
This press release may contain statements which constitute forward
looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, including statements regarding the
intent, belief or current expectations of the Company, its directors, or
its officers with respect to the future operating performance of the
Company and our success with respect to the integration and
consolidation. Investors are cautioned that any such forward looking
statements are not guarantees of future performance and involve risk and
uncertainties, and that actual results may differ materially form those
in the forward looking statements as a result of various factors.
Important factors that could cause such differences are described in the
Company’s periodic filings with the Securities and Exchange Commission.
BioScrip, Inc.
Michael Krivich, 815-302-4122
